当前位置：
X-MOL 学术
›
Cell. Mol. Immunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment.
Cellular & Molecular Immunology ( IF 21.8 ) Pub Date : 2020-03-24 , DOI: 10.1038/s41423-020-0406-y Lambertus P van den Heuvel 1, 2, 3 , Nicole C A J van de Kar 1 , Caroline Duineveld 4 , Andrei Sarlea 1 , Thea J A M van der Velden 1 , Wilhelmus T B Liebrand 1 , Sanne van Kraaij 2 , Camilla Schjalm 5 , Romy Bouwmeester 1 , Jack F M Wetzels 4 , Tom E Mollnes 5, 6, 7 , Elena B Volokhina 1, 2
中文翻译：
依库丽单抗治疗期间，补体成分C5不负责兔红细胞溶血测定中的替代途径活性。
更新日期：2020-03-24
Cellular & Molecular Immunology ( IF 21.8 ) Pub Date : 2020-03-24 , DOI: 10.1038/s41423-020-0406-y Lambertus P van den Heuvel 1, 2, 3 , Nicole C A J van de Kar 1 , Caroline Duineveld 4 , Andrei Sarlea 1 , Thea J A M van der Velden 1 , Wilhelmus T B Liebrand 1 , Sanne van Kraaij 2 , Camilla Schjalm 5 , Romy Bouwmeester 1 , Jack F M Wetzels 4 , Tom E Mollnes 5, 6, 7 , Elena B Volokhina 1, 2
Affiliation
|
中文翻译：
依库丽单抗治疗期间，补体成分C5不负责兔红细胞溶血测定中的替代途径活性。
京公网安备 11010802027423号